Miroux C, Moralès O, Carpentier A, Dharancy S, Conti F, Boleslowski E, Podevin P, Auriault C, Pancré V, Delhem N
CNRS (Unité Mixte de Recherche: 8161) - Institut de Biologie de Lille, Lille, France.
Transplant Proc. 2009 Oct;41(8):3371-4. doi: 10.1016/j.transproceed.2009.08.043.
Inevitable hepatitis C virus (HCV) recurrence after liver transplantation is a major barrier to the survival of a transplanted liver. It may be promoted by immunosuppression and the emergence of CD4+CD25+ regulatory T cells (Treg). Treg cells can mediate the induction and maintenance of immunological self-tolerance as well as transplant tolerance. We investigated the effects of cyclosporine (CsA), a widely used immunosuppressive agent, on human CD4+CD25+ Treg cells.
Human CD4+CD25+ cells isolated from healthy donors were cultured in the presence of 40 or 400 ng/mL CsA. The suppressive activity of Treg was assessed in mixed leukocyte reactions (MLR) using CD25+ and autologous activated peripheral blood mononuclear cells (PBMC). Phenotype analysis (flow cytometric, Q-PCR) and cytokine production (ELISA) of Treg cells were then performed on cultures.
CsA (40 or 400 ng/mL) inhibited the proliferative capacity of PBMC and CD4+CD25+ Treg in a dose-dependent manner. Interestingly, addition of 40 ng/mL CsA in MLR impaired the suppressive activity of CD4+CD25+ cells, whereas a higher dose of CsA had no effect on Treg function. It appears that a therapeutic dose of CsA (40 ng/mL) did not change the phenotype of CD4+CD25+ T cells, but altered Treg activity by switching the regulatory to an inflammatory cytokine profile.
CsA significantly impaired the function of CD4+CD25+ Treg cells by inducing interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) secretion. The present studies suggested that CsA may block the induction of immune tolerance and decrease the risk of hepatitis C recurrence.
肝移植后不可避免的丙型肝炎病毒(HCV)复发是移植肝存活的主要障碍。免疫抑制以及CD4+CD25+调节性T细胞(Treg)的出现可能会促进其复发。Treg细胞可介导免疫自身耐受以及移植耐受的诱导和维持。我们研究了广泛使用的免疫抑制剂环孢素(CsA)对人CD4+CD25+ Treg细胞的影响。
从健康供体分离出的人CD4+CD25+细胞在存在40或400 ng/mL CsA的情况下进行培养。使用CD25+和自体活化外周血单个核细胞(PBMC)在混合淋巴细胞反应(MLR)中评估Treg的抑制活性。然后对培养物进行Treg细胞的表型分析(流式细胞术、定量聚合酶链反应)和细胞因子产生(酶联免疫吸附测定)。
CsA(40或400 ng/mL)以剂量依赖性方式抑制PBMC和CD4+CD25+ Treg的增殖能力。有趣的是,在MLR中添加40 ng/mL CsA会损害CD4+CD25+细胞的抑制活性,而更高剂量的CsA对Treg功能没有影响。似乎治疗剂量的CsA(40 ng/mL)不会改变CD4+CD25+ T细胞的表型,但通过将调节性细胞因子谱转变为炎性细胞因子谱来改变Treg活性。
CsA通过诱导白细胞介素-2(IL-2)和干扰素-γ(IFN-γ)分泌显著损害CD4+CD25+ Treg细胞的功能。本研究表明,CsA可能会阻断免疫耐受的诱导并降低丙型肝炎复发的风险。